| 1 |
Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022;16:721-35. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
|
| 2 |
Yasmin F, Najeeb H, Naeem U, Moeed A, Koritala T, Surani S. Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease. World J Clin Cases 2022; 10(21): 7195-7208 [DOI: 10.12998/wjcc.v10.i21.7195] [Reference Citation Analysis]
|
| 3 |
Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Tanida S, Ozeki K, Kanno T, Katano T, Sugimura N, Nishie H, Iwasaki H, Tanaka M, Shimura T, Kubota E, Kataoka H. Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. J Clin Med Res 2021;13:510-4. [PMID: 34925662 DOI: 10.14740/jocmr4625] [Reference Citation Analysis]
|
| 5 |
Vasile Balaban D, Jinga M. Apheresis in Inflammatory Bowel Disease: Current Evidence. Crohn’s Disease Recent Advances 2021. [DOI: 10.5772/intechopen.93605] [Reference Citation Analysis]
|
| 6 |
Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Kiss S, Németh D, Hegyi P, Földi M, Szakács Z, Erőss B, Tinusz B, Hegyi PJ, Sarlós P, Alizadeh H. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. BMJ Open 2021;11:e042374. [PMID: 34011580 DOI: 10.1136/bmjopen-2020-042374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 9 |
Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Tanida S, Ozeki K, Mizoshita T, Kitagawa M, Ozeki T, Tanaka M, Nishie H, Shimura T, Kubota E, Kataoka H. Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. J Clin Med Res 2020;12:36-40. [PMID: 32010420 DOI: 10.14740/jocmr4037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 11 |
Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196. [PMID: 31752695 DOI: 10.1186/s12876-019-1110-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Fukuchi T, Koga H, Kaichi S, Ishikawa A, Horita T, Araki R, Yokota A, Namba Y, Kyo M, Eguchi T, Shimazu K. Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis Is Suitable for Elderly Patients With Active Ulcerative Colitis Taking no Corticosteroids or Biologics. Ther Apher Dial. 2019;23:224-232. [PMID: 31025824 DOI: 10.1111/1744-9987.12819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 14 |
Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol 2018;18:120. [PMID: 30068300 DOI: 10.1186/s12876-018-0853-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170. [PMID: 29977035 DOI: 10.1038/s41424-018-0037-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
Shimazu K, Fukuchi T, Kim I, Noguchi Y, Iwata M, Koyama S, Ubukata S, Tanaka A. Efficacy and Usefulness of New Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis in Active Ulcerative Colitis Patients Without Corticosteroids and Biologics. Ther Apher Dial. 2016;20:383-389. [PMID: 27523079 DOI: 10.1111/1744-9987.12470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 17 |
Fascì-Spurio F, Meucci G, Papi C, Saibeni S; IG-IBD (Italian Group for Inflammatory Bowel Disease). The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. Dig Liver Dis 2017;49:1092-7. [PMID: 28801181 DOI: 10.1016/j.dld.2017.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 18 |
Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol 2017;11:749-58. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Nomura O, Osada T, Shibuya T, Ishikawa D, Haga K, Kodani T, Sakamoto N, Ogihara T, Yamaji K, Watanabe S. Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis. J Clin Apher. 2018;33:21-28. [PMID: 28581039 DOI: 10.1002/jca.21555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 20 |
Gerçeker E, Yüceyar H, Kasap E, Demirci U, Ekti BC, Aydoğdu İ, Miskioğlu M. Treatment of inflammatory bowel disease by leukocytapheresis. Transfus Apher Sci 2017;56:421-6. [PMID: 28454883 DOI: 10.1016/j.transci.2017.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 21 |
Tanida S, Mizoshita T, Nishie H, Ozeki K, Katano T, Kubota E, Kataoka H, Kamiya T, Joh T. Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. J Clin Med Res. 2015;7:884-889. [PMID: 26491502 DOI: 10.14740/jocmr2333w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 23 |
Takayama T, Okamoto S, Hisamatsu T, Naganuma M, Matsuoka K, Mizuno S, Bessho R, Hibi T, Kanai T. Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. PLoS One 2015;10:e0131197. [PMID: 26111148 DOI: 10.1371/journal.pone.0131197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 24 |
Fowler S, Jones J, Hull PR, Ghosh S. Extracorporeal photopheresis for the treatment of Crohn's disease. Transfusion and Apheresis Science 2015;52:183-6. [DOI: 10.1016/j.transci.2015.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 25 |
Osada T, Watanabe S. Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives. Juntendo Medical Journal 2015;61:588-596. [DOI: 10.14789/jmj.61.588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 26 |
De Cassan C, Savarino E, Marson P, Tison T, Hatem G, Sturniolo GC, D’Incà R. Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. World J Gastroenterol 2014; 20(45): 17155-17162 [PMID: 25493030 DOI: 10.3748/wjg.v20.i45.17155] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 27 |
Byrne WL, Murphy CT, Cronin M, Wirth T, Tangney M. Bacterial-mediated DNA delivery to tumour associated phagocytic cells. J Control Release 2014;196:384-93. [PMID: 25466954 DOI: 10.1016/j.jconrel.2014.10.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 28 |
Olsen HH, Muratov V, Cederlund K, Lundahl J, Eklund A, Grunewald J. Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action. Clin Exp Immunol 2014;177:712-9. [PMID: 24773420 DOI: 10.1111/cei.12360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 29 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 30 |
Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 31 |
Fukuchi T, Nakase H, Ubukata S, Matsuura M, Yoshino T, Toyonaga T, Shimazu K, Koga H, Yamashita H, Ito D. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn’s disease. BMC Gastroenterol. 2013;13:124. [PMID: 25015328 DOI: 10.1186/1471-230x-14-124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 32 |
Schultheiß C, Weischenberg R, Herrmann A, Haller B, Schmid RM, Reindl W, Huber W. Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis. Artif Organs 2015;39:187-92. [PMID: 24981894 DOI: 10.1111/aor.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 33 |
Fujisawa T, Tawada C, Mizutani Y, Doi T, Yoshida S, Ogura S, Seishima M. Efficacy of Granulocyte and Monocyte Adsorption Apheresis for Treatment of Palmoplantar Pustulosis: The Efficacy of GMA for PPP. Ther Apher Dial 2014;18:238-43. [DOI: 10.1111/1744-9987.12210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, Chiba T. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis 2014;46:219-26. [PMID: 24268950 DOI: 10.1016/j.dld.2013.10.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 35 |
Denmark VK, Mayer L. Inflammatory Bowel Diseases. The Autoimmune Diseases 2014. [DOI: 10.1016/b978-0-12-384929-8.00060-5] [Reference Citation Analysis]
|
| 36 |
Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis 2013;7:e49-54. [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 37 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 38 |
Winters JL. Randomized controlled trials in therapeutic apheresis: Randomized Trials in Apheresis. J Clin Apheresis 2013;28:48-55. [DOI: 10.1002/jca.21263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 39 |
Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 40 |
Hanai H, Iida T, Ikeya K, Abe J, Maruyama Y, Shimura T, Sugimoto K, Watanabe F. A new paradigm in ulcerative colitis: regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance. Mol Immunol. 2013;54:173-180. [PMID: 23280396 DOI: 10.1016/j.molimm.2012.11.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 41 |
Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18(41): 5833-5838 [PMID: 23139598 DOI: 10.3748/wjg.v18.i41.5833] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 42 |
Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012;6:750-5. [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 43 |
Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol 2012;47:359-65. [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 44 |
Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 45 |
Kochi S, Nakamura S, Matsumoto T. Efficacy of low-dose thiopurine therapy for the induction of remission in steroid-dependent ulcerative colitis: Comparison with cytapheresis. OJGas 2012;02:9-14. [DOI: 10.4236/ojgas.2012.21002] [Reference Citation Analysis]
|
| 46 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 47 |
Passalacqua S, Ferraro PM, Bresci G, D'Ovidio V, Astegiano M, Principi M, Testa R, D'Incà R, Valpiani D, Armuzzi A, Sablich R, Cavallaro F, Costa F, Di Leo V, Colombo E, Santini A, Aratari A, Lecis P, Saladino V, Riegler G, Marco M, Calella F, Ricci C, Guidi ML, Repaci G, Silla M. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher 2011;26:332-7. [PMID: 22072543 DOI: 10.1002/jca.20315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 48 |
Zhu M, Xu X, Nie F, Tong J, Xiao S, Ran Z. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis 2011;26:999-1007. [PMID: 21476027 DOI: 10.1007/s00384-011-1193-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 49 |
Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol 2011;46:1003-9. [PMID: 21681409 DOI: 10.1007/s00535-011-0428-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 50 |
Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 2011;46:129-37. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 51 |
Ng SC, Chan FK, Sung JJ. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:417-27. [PMID: 21138457 DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 52 |
Thanaraj S, Hamlin PJ, Ford AC. Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther 2010;32:1297-306. [PMID: 21050231 DOI: 10.1111/j.1365-2036.2010.04490.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 53 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 54 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 55 |
Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010;16:1905-11. [PMID: 20310015 DOI: 10.1002/ibd.21260] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 56 |
Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010;34:645-8. [PMID: 20971590 DOI: 10.1016/j.gcb.2010.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 57 |
Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687-695. [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 58 |
Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177. [PMID: 20568098 DOI: 10.1002/jca.20240] [Cited by in Crossref: 385] [Cited by in F6Publishing: 412] [Article Influence: 29.6] [Reference Citation Analysis]
|
| 59 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 60 |
Takeda S, Sato T, Katsuno T, Nakagawa T, Noguchi Y, Yokosuka O, Saito Y. Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis. Dig Dis Sci 2010;55:1886-95. [PMID: 19908144 DOI: 10.1007/s10620-009-0974-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 61 |
Ibargoyen-Roteta N, Gutiérrez-Ibarluzea I, Rico-Iturrioz R, López-Argumedo M, Reviriego-Rodrigo E, Cabriada-Nuño JL, Schünemann HJ. The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci 2010;5:48. [PMID: 20553616 DOI: 10.1186/1748-5908-5-48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 62 |
Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis 2010;42:432-5. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci 2010;55:1421-8. [PMID: 19517236 DOI: 10.1007/s10620-009-0845-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 64 |
Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646-654. [PMID: 20227580 DOI: 10.1016/j.jaad.2009.05.030] [Cited by in Crossref: 146] [Cited by in F6Publishing: 156] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 65 |
Yamaguchi T, Yoshida S, Tanaka S, Takemura Y, Oka S, Yoshihara M, Yamada H, Chayama K. Predicting the clinical response to cytapheresis in steroid-refractory or -dependent ulcerative colitis using contrast-enhanced ultrasonography. Scand J Gastroenterol 2009;44:831-7. [PMID: 19811342 DOI: 10.1080/00365520902839659] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 67 |
Helmy A, Abdulla M, Kagevi I, Al Kahtani K. Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol 2009;15:283-7. [PMID: 19794281 DOI: 10.4103/1319-3767.56093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 68 |
Nos P, Domènech E. Tratamiento con aféresis en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2009;32:509-18. [DOI: 10.1016/j.gastrohep.2009.01.183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 69 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 70 |
Ruuska T, Wewer V, Lindgren F, Malmborg P, Lindquist M, Marthinsen L, Browaldh L, Casswall T, Kalliomäki M, Grönlund J. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives. Inflamm Bowel Dis 2009;15:1049-54. [PMID: 19137602 DOI: 10.1002/ibd.20859] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 71 |
Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009;15:935-50. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 72 |
Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y, Takahashi D, Kawana I, Suzuki S, Umemura S. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009;15:328-34. [PMID: 18942752 DOI: 10.1002/ibd.20759] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 73 |
Bresci G. Granulocytapheresis in the treatment of patients with active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:639-43. [PMID: 19072341 DOI: 10.1586/17474124.2.5.639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 74 |
Waitz G, Petermann S, Liebe S, Emmrich J, Ramlow W. Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis. Dig Dis Sci 2008;53:2507-15. [PMID: 18253828 DOI: 10.1007/s10620-007-0168-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 75 |
Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008;40:731-6. [PMID: 18387860 DOI: 10.1016/j.dld.2008.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 76 |
Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S; Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-9. [PMID: 18602921 DOI: 10.1053/j.gastro.2008.04.023] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 77 |
Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-516. [PMID: 18665138 DOI: 10.1038/ncpgasthep1209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 78 |
Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 2008;77:96-107. [PMID: 18382085 DOI: 10.1159/000122473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 79 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 80 |
Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for pustular psoriasis. Ther Apher Dial 2008;12:13-8. [PMID: 18257807 DOI: 10.1111/j.1744-9987.2007.00536.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 81 |
Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr 2008;46:386-91. [PMID: 18367949 DOI: 10.1097/MPG.0b013e31815604e5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 82 |
Nakamura T, Nagahori M, Kanai T, Watanabe M. Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis. Digestion 2008;77 Suppl 1:36-41. [PMID: 18204260 DOI: 10.1159/000111486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 83 |
Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 155] [Cited by in F6Publishing: 163] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 84 |
Noble A, Baldassano R, Mamula P. Novel therapeutic options in the inflammatory bowel disease world. Dig Liver Dis 2008;40:22-31. [PMID: 17988966 DOI: 10.1016/j.dld.2007.07.169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 85 |
Noguchi A, Watanabe K, Narumi S, Yamagami H, Fujiwara Y, Higuchi K, Oshitani N, Arakawa T. The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol 2007;42:947-56. [PMID: 18085351 DOI: 10.1007/s00535-007-2118-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 86 |
Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther Apher Dial. 2007;11:177-182. [PMID: 17497998 DOI: 10.1111/j.1744-9987.2007.00424.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 87 |
Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007;26:779-94. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 88 |
Kanke K, Hoshino M, Tominaga K, Nakano M, Terano A, Hiraishi H. Selection of Anticoagulants for Leukocytapheresis Therapy in Cases of Active Ulcerative Colitis. Blood Purif 2007;25:370-6. [DOI: 10.1159/000107712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 89 |
Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007;39:626-33. [PMID: 17532273 DOI: 10.1016/j.dld.2007.04.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 90 |
Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis 2007;39:617-25. [PMID: 17531555 DOI: 10.1016/j.dld.2007.03.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 91 |
Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 2007;39:435-7. [PMID: 17379590 DOI: 10.1016/j.dld.2007.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 92 |
Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, Sakaguchi K, Shiratori Y. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis 2007;39:422-9. [PMID: 17379587 DOI: 10.1016/j.dld.2007.01.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 93 |
Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panés J. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007; 13(15): 2193-2197 [PMID: 17465500 DOI: 10.3748/wjg.v13.i15.2193] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 94 |
Matsumoto T, Fukunaga K, Kusaka T, Onishi K, Yokoyama Y, Ohda Y, Jinno Y, Hida N, Yoshida K. Depleting phagocytes. Falk Symposium. [DOI: 10.1007/978-1-4020-5702-1_34] [Reference Citation Analysis]
|
| 95 |
Luis Cabriada-nuño J, Bernal-martínez A, Hernández-martín A, Antonio Arévalo-serna J, Fernández-prado E. Aféresis leucocitaria en la inducción de la remisión y retirada de corticoides en la colitis ulcerosa corticodependiente. Diálisis y Trasplante 2007;28:47-55. [DOI: 10.1016/s1886-2845(07)71352-8] [Reference Citation Analysis]
|
| 96 |
Emmrich J. Leucocytapheresis. Falk Symposium. [DOI: 10.1007/1-4020-4316-3_24] [Reference Citation Analysis]
|
| 97 |
Afenyi-annan A, Brecher ME, Bandarenko N. Update on multi-center clinical trials in the United States. Transfusion and Apheresis Science 2007;36:5-12. [DOI: 10.1016/j.transci.2006.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 98 |
Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis. J Clin Apheresis 2007;22:106-75. [DOI: 10.1002/jca.20129] [Cited by in Crossref: 181] [Cited by in F6Publishing: 189] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 99 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 100 |
Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-8. [PMID: 17004123 DOI: 10.1007/s10620-006-9199-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 101 |
Ikeda H, Ishimaru Y, Takayasu H, Fujino J, Kisaki Y, Otani Y, Yamagishi J, Tahara K. Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr 2006;43:592-6. [PMID: 17130733 DOI: 10.1097/01.mpg.0000237928.07729.79] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 102 |
Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 2006;86:1045-1064. [PMID: 16905423 DOI: 10.1016/j.suc.2006.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 103 |
Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin Pharmacother 2006;7:1907-18. [PMID: 17020417 DOI: 10.1517/14656566.7.14.1907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 104 |
Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 2006;40:482-9. [PMID: 16825929 DOI: 10.1097/00004836-200607000-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 105 |
Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 106 |
Manoj K, Sigurbjornsson FT, Bjarnason I. Leucocyte apheresis for ulcerative colitis: Where do we stand? Dig Liver Dis 2006;38:394-6. [PMID: 16551515 DOI: 10.1016/j.dld.2006.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 107 |
Cabriada JL, Doménech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, Jiménez-López CE, Nos P, Obrador A, Panès J, Saro C, Varea V, Lafuente R, Guilera M. [Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease]. Gastroenterol Hepatol 2006;29:85-92. [PMID: 16448611 DOI: 10.1157/13083905] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 108 |
Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006; 12(4): 520-525 [PMID: 16489663 DOI: 10.3748/wjg.v12.i4.520] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 109 |
Pineda AA. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12 Suppl 1:S10-4. [PMID: 16378005 DOI: 10.1097/01.mib.0000195386.19268.b3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 110 |
Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12 Suppl 1:S15-21. [PMID: 16378006 DOI: 10.1097/01.mib.0000195387.26892.22] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 111 |
Palmon R, Mayer LF. Inflammatory Bowel Diseases: Ulcerative Colitis and Crohn's Disease. The Autoimmune Diseases 2006. [DOI: 10.1016/b978-012595961-2/50055-x] [Reference Citation Analysis]
|
| 112 |
Kugathasan S, Dubinsky MC, Keljo D, Moyer MS, Rufo PA, Wyllie R, Zachos M, Hyams J. Severe colitis in children. J Pediatr Gastroenterol Nutr 2005;41:375-85. [PMID: 16205502 DOI: 10.1097/01.mpg.0000186272.65559.ce] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 113 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kikuyama M, Tanaka T, Kondo K, Tanaka K, Takai K. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol 2005; 11(20): 3085-3090 [PMID: 15918195 DOI: 10.3748/wjg.v11.i20.3085] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
|
